Yahoo Αναζήτηση Διαδυκτίου

Αποτελέσματα Αναζήτησης

1. www.accessdata.fda.gov › drugsatfda_docs › labelORTHO EVRA® (norelgestromin / ethinyl estradiol TRANSDERMAL...

   www.accessdata.fda.gov › drugsatfda_docs › label

   ORTHO EVRA ® is a combination transdermal contraceptive patch with a contact surface area of 20 cm. 2. It contains 6.00 mg norelgestromin (NGMN) and 0.75 mg ethinyl estradiol (EE). Systemic...

2. cdn.mdedge.com › files › s3fs-publicORTHO EVRA (NORELGESTROMIN / ETHINYL ESTRADIOL TRANSDERMAL...

   cdn.mdedge.com › files › s3fs-public

   ORTHO EVRA® is a combination transdermal contraceptive patch with a contact surface area of 20 cm 2 .It contains 6.00 mg norelgestromin and 0.75 mg ethinyl estradiol (EE),and releases 150 micrograms of norelgestromin and 20 micrograms of EE to the bloodstream per 24 hours.

3. pdf.hres.ca › dpd_pm › 00065628PRODUCT MONOGRAPH - pdf.hres.ca

   pdf.hres.ca › dpd_pm › 00065628

   The EVRA® (norelgestromin and ethinyl estradiol) transdermal system is indicated for the prevention of pregnancy. The pharmacokinetic profile for the EVRA ® transdermal system is different from that of

4. www.emjreviews.com › 11 › EVRA-PI-GB-November-2021_UK-EVR-2100006_CERTIFIEDEVRA® 203 micrograms/24 hours + 33.9 micrograms/24 hours...

   www.emjreviews.com › 11 › EVRA-PI-GB-November-2021_UK-EVR-2100006_CERTIFIED

   EVRA® 203 micrograms/24 hours + 33.9 micrograms/24 hours transdermal patch PRESCRIBING INFORMATION . ACTIVE INGREDIENT(S): Norelgestromin (NGMN) and ethinyl estradiol (EE). Please refer to Summary of Product Characteristics (SmPC) before prescribing. INDICATION(S): Female contraception, intended for women of fertile age. Safety/efficacy

5. www.ema.europa.eu › product-information › evra-epar-product-information_enANNEX I SUMMARY OF PRODUCT CHARACTERISTICS - European Medicines...

   www.ema.europa.eu › product-information › evra-epar-product-information_en

   1. NAME OF THE MEDICINAL PRODUCT. EVRA 203 micrograms/24 hours + 33.9 micrograms/24 hours transdermal patch. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION. Each 20 cm2 transdermal patch contains 6 mg norelgestromin (NGMN) and 600 micrograms ethinyl estradiol (EE).

6. www.ema.europa.eu › en › medicinesEvra - European Medicines Agency (EMA)

   www.ema.europa.eu › en › medicines

   • Αποθηκευμένο αντίγραφο

   For more information about treatment with Evra, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. Evra : EPAR - Summary for the public English (EN) (77.66 KB - PDF)

7. www.accessdata.fda.gov › drugsatfda_docs › labelThis label may not be the latest approved by FDA. For current...

   www.accessdata.fda.gov › drugsatfda_docs › label

   ORTHO EVRA is an estrogen/progestin combination hormonal contraceptive (CHC), indicated for the prevention of pregnancy in women who elect to use a transdermal patch. (1) Limitation of Use:...